Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram with or without tandospirone in vascular depression-related sleep and cognitive disorders
ChiCTR2300075407Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram and tandospirone in vascular depression (VD), sleep disorder and confusion (3 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Polysomnography parameters at week 12 and Neuropsychological assessment at week 12. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
escitalopramtandospirone
03
Conditions
vascular depression (VD)sleep disorderconfusion
Beyond the preview
Go deeper on ChiCTR2300075407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075407.